Analysis of follow-up results after percutaneous coronary intervention in patients with primary thrombocythemia
10.3969/j.issn.1004-8812.2018.04.005
- VernacularTitle:原发性血小板增多症患者经皮冠状动脉介入治疗随访结果分析
- Author:
Ye-Chen HAN
1
;
Hong-Zhi XIE
;
Shu-Yang ZHANG
Author Information
1. 中国医学科学院 北京协和医学院 北京协和医院心内科
- Keywords:
Essential thrombocythemia;
Coronary heart disease;
Percutaneous coronary intervention
- From:
Chinese Journal of Interventional Cardiology
2018;26(4):209-212
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the characteristics, treatment and prognosis during follow-up in patients with essential thrombocythemia(ET)after percutaneous coronary intervention(PCI). Methods A total of 9 patients with ET who had CAD and treated with PCI in our hospital from 2010-01 to 2017-07 were retrospectively studied. The basic clinical information with clinical data,data of coronary intervention,application of anti-platelet and platelet reducing drugs,and the results of long-term follow-up were recorded in all patients. Results There were 5 male and 4 female with a mean age of (60.9 ± 14.3) years The 9 patients included 3 cases of acute myocardial infaction(MI),3 cases of old MI,2 cases of unstable angina and 2 cases stable angina. Coronary angiography revealed that there were 4 cases with single vessle involved and 5 cases with two-three vessles involved. All the patients were implante with drug-eluting stents. The mean platelet counts of the patients at admission were(596±233)×109/L. In 4 patients, ET was diagnosed during current hospitalization and their mean platelet counts were(803±105)×109/L. All patients received dual anti-platelet drugs after PCI and 8 patients had hydroxyurea during follow-up. During the follow-up of (53.2±26.9) months,no cardiovascular events occurred. One case of gastrointestinal bleeding occurred during the follow-up due to gastric ulcer. Conclusions Application of platelet reducing therapy with dual anti-platelet drugs in ET patients after PCI is eff ective and safe.
